WO2007016350A3 - Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees - Google Patents

Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees Download PDF

Info

Publication number
WO2007016350A3
WO2007016350A3 PCT/US2006/029427 US2006029427W WO2007016350A3 WO 2007016350 A3 WO2007016350 A3 WO 2007016350A3 US 2006029427 W US2006029427 W US 2006029427W WO 2007016350 A3 WO2007016350 A3 WO 2007016350A3
Authority
WO
WIPO (PCT)
Prior art keywords
mechanical properties
modified release
release tablet
tablet formulations
enhanced mechanical
Prior art date
Application number
PCT/US2006/029427
Other languages
English (en)
Other versions
WO2007016350A2 (fr
Inventor
Amir H Shojaei
Melissa E Culp
Original Assignee
Supernus Pharmaceuticals Inc
Amir H Shojaei
Melissa E Culp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc, Amir H Shojaei, Melissa E Culp filed Critical Supernus Pharmaceuticals Inc
Priority to CA002616845A priority Critical patent/CA2616845A1/fr
Priority to EP06788799A priority patent/EP1909767A2/fr
Priority to JP2008524198A priority patent/JP2009502957A/ja
Publication of WO2007016350A2 publication Critical patent/WO2007016350A2/fr
Publication of WO2007016350A3 publication Critical patent/WO2007016350A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de préparation d'un médicament sous forme posologique solide présentant une dureté spécifiée, ce médicament contenant au moins un agent pharmaceutiquement actif présentant un profil de libération dépendant du pH, au moins un agent à libération prolongée non dépendante du pH, et une dose efficace d'Eudragit L100-55.
PCT/US2006/029427 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees WO2007016350A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002616845A CA2616845A1 (fr) 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees
EP06788799A EP1909767A2 (fr) 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees
JP2008524198A JP2009502957A (ja) 2005-07-28 2006-07-28 機械的特性の向上した徐放性錠剤配合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70300005P 2005-07-28 2005-07-28
US60/703,000 2005-07-28

Publications (2)

Publication Number Publication Date
WO2007016350A2 WO2007016350A2 (fr) 2007-02-08
WO2007016350A3 true WO2007016350A3 (fr) 2007-05-31

Family

ID=37692541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029427 WO2007016350A2 (fr) 2005-07-28 2006-07-28 Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees

Country Status (4)

Country Link
EP (1) EP1909767A2 (fr)
JP (1) JP2009502957A (fr)
CA (1) CA2616845A1 (fr)
WO (1) WO2007016350A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087663A2 (fr) * 2007-11-30 2009-07-16 Sun Pharmaceutical Industries Ltd. Comprimé oral enrobé à libération contrôlée
LT2364360T (lt) 2008-11-13 2017-08-10 Nogra Pharma Limited Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
PL2531181T3 (pl) * 2010-02-03 2019-09-30 Pharma Two B Ltd. Preparaty rasagiliny o przedłużonym uwalnianiu i ich zastosowanie
CN102138906B (zh) * 2011-04-11 2012-09-05 合肥合源药业有限公司 一种盐酸可乐定缓释微丸制剂
TW202400130A (zh) 2022-06-15 2024-01-01 日商澤井製藥股份有限公司 含胍法辛鹽酸鹽製劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168404A1 (en) * 1998-07-20 2002-11-14 Isabelle Rault Use of an acrylic type polymer as disintegrating agent
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168404A1 (en) * 1998-07-20 2002-11-14 Isabelle Rault Use of an acrylic type polymer as disintegrating agent
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OFOEFULE S I ET AL: "USE OF ACRYCLIC AND METACRYLIC ACID DERIVATIVES AS SUSTAINED RELEASE MATRICES FOR THEOPHYLLINE HYDRATE TABLETS", BOLLETTINO CHIMICO FARMACEUTICO, SOCIETA EDITORIALE FARMACEUTICA, MILANO, IT, vol. 138, no. 10, 1999, pages 526 - 530, XP001030890, ISSN: 0006-6648 *
SCHULZE M D ET AL: "Indices of tableting performance for acrylic resin polymers with plastic and brittle drugs", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 1993 UNITED STATES, vol. 19, no. 12, 1993, pages 1393 - 1411, XP008077210, ISSN: 0363-9045 *
TAKKA S ET AL: "INFLUENCE OF METHACRYLIC ACID AND HYDROXYPROPYLMETHYL CELLULOSE ON THE TABLET PROPERTIES AND IN VITRO RELEASE OF DEXTROMETHORPHAN HYDROBROMIDE", PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 58, no. 12, December 2003 (2003-12-01), pages 886 - 890, XP001178399, ISSN: 0031-7144 *

Also Published As

Publication number Publication date
JP2009502957A (ja) 2009-01-29
EP1909767A2 (fr) 2008-04-16
WO2007016350A2 (fr) 2007-02-08
CA2616845A1 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
WO2011049706A8 (fr) Comprimés oralement transformables
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
WO2010035273A3 (fr) Nouveau système de délivrance gastro-rétentif
TR200200562T2 (tr) Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
WO2006124047A3 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
WO2006084164A3 (fr) Systeme d'administration a retention gastrique et a liberation lente
MX2009008952A (es) Microesferas que comprenden una matriz de sustancia activa resistente a jugo gastrico.
EP1783137A4 (fr) Dérivé de galactose, vecteur de médicament et préparation thérapeutique
WO2007050294A3 (fr) Formes posologiques liquides possedant des proprietes enteriques de liberation retardee et ensuite prolongee
IL188744A0 (en) High drug load formulations and dosage forms
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
WO2007016350A3 (fr) Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
WO2009045795A3 (fr) Formulations galéniques de composés organiques
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2010052466A8 (fr) Composition pharmaceutique en aérosol
WO2008128191A3 (fr) Formes dosifiees orales de cephalotaxine
WO2007075980A3 (fr) Comprimes de lansoprazole se desintegrant oralement
WO2006021692A8 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
WO2006050246A3 (fr) Formulations de medicaments insolubles dans l'eau ou faiblement solubles dans l'eau dans des particules de glycosaminoglycane lipides et leur utilisation dans des diagnostics et une therapie
HK1120417A1 (en) Stable nanoparticle formulations
WO2002034240A3 (fr) Formulations a liberation retardee et prolongee et procede d'utilisation

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2616845

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008524198

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006788799

Country of ref document: EP